Following a period of sustained growth, life science logistics company Biocair has relocated and expanded its Chicago office and warehouse facility. As part of its wider global growth strategy, the leading specialist has increased its 2,904 sq. ft. space by more than double, securing a new 7,213 sq. ft. facility just three miles from the key cargo complex at O’Hare International Airport.
News
New 60,000 sq ft multi-occupancy building will provide additional space for life science companies within Cambridge cluster
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).
Excellent to see Charles River, a Partner of One Nucleus, making progress (5 years ahead of schedule!) towards helping achieve 100% renewable electricity globally. Read more to find out how...
Arecor Therapeutics plc
(“Arecor” or the “Group”)
FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE
First commercial sale triggers milestone payment and future royalties to Arecor
Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.
The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.
Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund
Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
Amsterdam, the Netherlands and London, UK – 15 November 2023 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board.